The GTSE1 (G2 and S-phase Expressed 1) antibody is a research tool designed to detect and study the GTSE1 protein, a cell cycle-regulated molecule implicated in cancer progression and therapeutic resistance. GTSE1 expression peaks during the G2 and S phases of the cell cycle and is linked to microtubule dynamics, DNA damage response, and p53 regulation. It interacts with p53 to promote its cytoplasmic sequestration, thereby inhibiting p53-mediated apoptosis and cell cycle arrest—a mechanism exploited by cancer cells to evade tumor suppression. Overexpression of GTSE1 has been observed in various cancers, including breast, lung, and gastric cancers, correlating with poor prognosis, metastasis, and chemoresistance. The GTSE1 antibody enables researchers to investigate these roles through techniques like Western blotting, immunofluorescence, and immunohistochemistry. Its applications extend to studying cancer biology, identifying biomarkers, and exploring therapeutic targets. Recent studies also suggest GTSE1's involvement in mitotic fidelity and chromosomal stability, highlighting its broader relevance in genomic integrity. As a reagent, the antibody’s specificity and validation across experimental models remain critical for elucidating GTSE1’s dual roles in normal cell cycle regulation and oncogenic pathways.